A new Minnesota cover crop could help make air travel greener, UMN St. Paul researchers say
The agency has announced that it will fund a $75,000 grant for the University of Minnesota's Forever Green Initiative for an independent study on how the state can scale up to 1 million acres of winter camelina, MPCA commissioner Katrina Kessler said Tuesday at the university's crop research fields in Falcon Heights.
'I think this is a great opportunity to support rural Minnesota, rural communities, farmers who want to innovate – and decarbonize the airline industry to help us meet our goals around getting to carbon neutral in 2050 as a state,' Kessler said.
Sustainable aviation fuel, or SAF, is fuel made from non-petroleum sources blended with traditional jet fuel to reduce greenhouse gas emissions. It can reduce aviation emissions by up to 94%, according to the MPCA.
Winter camelina has a high oil content and a low carbon intensity score, which makes it beneficial for sustainable aviation fuel, according to the MPCA. The crop also helps to improve soil health and water quality. Additionally, it can be used to create animal feed, food and bioplastic, according to Forever Green Initiative co-director Dr. Mitch Hunter.
'Right now, we don't have a pipeline, so to speak, built to take on farm production and turn it into fuel,' Hunter said. 'The study that we're launching will lay out the steps that we need to take to get there.'
In September 2024, Delta Air Lines used SAF derived in part from winter camelina to fuel a flight from Minneapolis to New York. The demonstration flight was the first out of Minneapolis-St. Paul International Airport to use SAF.
Every winter, about 17 million acres of cropland in Minnesota has nothing growing on it, according to Hunter. He said these cold months are a missed opportunity for farmers to grow crops like winter camelina, which is planted in the fall and harvested in the spring.
'If we can put productive, profitable crops on those acres that can protect the soil and give farmers something to harvest, we can make progress on improving farm economics, improving water quality and protecting the soil that we depend on for growing food today and for future generations,' Hunter said.
Close to 5000 acres of the crop were planted in the upper Midwest in the fall of 2024, according to Hunter, but the goal for Minnesota alone is to cover 1 million acres.
'We have an ambitious goal, which is to have 1 million acres of winter camelina in the upper Midwest by 2035,' Hunter said. 'We will really have to pull out all the stops to get to that goal, but we have a big, committed coalition of supporters who are all behind us in that goal, and that gives me hope that we can get there.'
The university and MPCA are encouraging farmers to consider growing winter camelina to help drive the demand for climate-smart crops.
Ben Penner, a farmer from Mankato, said that in 2024, Penner Farms planted close to 150 acres of winter camelina.
Penner said there hasn't been a crop to hit the market to help with fuel emissions like winter camelina and its relatives, since soybeans, which grows in the summer months and can also be used for sustainable aviation fuel. The potential for a crop like winter camelina is there, he said, but it's new and that means there's still a lot to learn.
'The demand is there, and it is a fuel pathway that will grow,' Penner said. 'What I tell farmers is, 'Let's learn everything we can now so that when that market comes fully online, then we'll be able to partake in the market rather than watch someone else do it.''
Along with soybeans and winter camelina, other crops that can be used as SAF feedstock include pennycress, woody biomass and corn, according to the MPCA.
'The journey that soybeans were on 80 years ago is the journey we're on with winter camelina; taking a promising plant and turning it into a high-performing crop,' Hunter said.
According to the MPCA, Gov. Tim Walz's 2025 budget includes $20 million over the next 10 years for tax credits to promote SAF production in Minnesota. In 2025, the state will also complete a roadmap for SAF industry development and regulation.
'This is part of our whole government approach around climate change,' Kessler said. 'We need to be doing whatever we can across the state, across all of our economic sectors to reduce greenhouse gases.'
Kessler and Hunter acknowledged that many environmental organizations and efforts have experienced federal funding cuts under the Trump administration and are unsure whether this will impact their plans.
'We were selected for a $10 million grant from the Department of Energy, which would greatly further our research on camelina and pennycress, and we understand that that grant is currently under review by the new administration,' Hunter said.
The world's biggest companies have caused $28 trillion in climate damage, a new study estimates
$50 million prize funded by Musk foundation goes to carbon-removal company that helps Indian farmers
84% of the world's coral reefs hit by worst bleaching event on record
Book Review: 'Hope Dies Last' visits visionaries fighting global warming
Mississippi River deemed most endangered river in U.S., conservation group says
Despite the uncertainty, Kessler and Hunter said the state remains committed to supporting this initiative.
'We remain hopeful that it will come through, and in the meantime, we are extra thankful for the support of all of these partners who can continue the work while we wait,' Hunter said.
The Forever Green Initiative is partnering with Greater MSP's MBOLD coalition and SAF Hub, Friends of the Mississippi River, Minnesota Environmental Partnership, the McKnight Foundation, MPCA and the Minnesota Department of Agriculture to conduct the study and fund the total cost of the research, which is between $250,000 to $500,000, according to the Minnesota Pollution Control Agency.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Associated Press
a day ago
- Associated Press
JCR Pharmaceuticals Announces the Achievement of Enrollment in the JR-141 Global Phase III Clinical Trial
HYOGO, Japan--(BUSINESS WIRE)--Jul 2, 2025-- JCR Pharmaceuticals Co., Ltd. (TSE 4552; JCR) announced that it achieved the enrollment of the target number of participants in the global Phase III clinical trial of JR-141 (INN: pabinafusp alfa), which is in development for the treatment of mucopolysaccharidosis type II (MPS II, also known as Hunter syndrome). The Phase III clinical trial is ongoing in the United States, Latin America, and Europe. ( JR-141-GS31 ) JR-141 is a recombinant fusion protein of an antibody against the human transferrin receptor and iduronate-2-sulfatase, the enzyme that is missing or malfunctioning in people with Hunter syndrome. JR-141 was developed using J-Brain Cargo ®, JCR's proprietary blood-brain barrier (BBB)-penetrating technology, which is designed to deliver biotherapeutics across the BBB into the central nervous system (CNS) to address the neurological symptoms of Hunter syndrome. 'This achievement is a milestone in the JR-141 clinical development program, as the Hunter syndrome community needs a therapy that treats the cognitive symptoms of this devastating and life-threatening disease for which there are inadequate treatment options available,' said Shin Ashida, Chairman, President and CEO of JCR Pharmaceuticals. 'We are making good progress in this global Phase III clinical trial, and we look forward to sharing the clinical data as they are available. Thank you to all the participants who are part of this clinical trial.' In March 2021, the Ministry of Health, Labour and Welfare (MHLW) in Japan approved JR-141 (also known by the brand name IZCARGO ® ) for a lysosomal storage disorder. JR-141 is the first-ever approved ERT in the world that penetrates the BBB. About JR-141 JR-141 (INN: pabinafusp alfa) is a recombinant fusion protein of an antibody against the human transferrin receptor and iduronate-2-sulfatase, the enzyme that is missing or malfunctioning in subjects with Hunter syndrome. It incorporates J-Brain Cargo ®, JCR's proprietary blood-brain barrier (BBB)-penetrating technology, to cross the BBB through transferrin receptor-mediated transcytosis, and its uptake into cells is mediated through the mannose-6-phosphate receptor. This novel mechanism of action is expected to make JR-141 effective against the central nervous system (CNS) symptoms of Hunter syndrome. In non-clinical trials, JCR has confirmed both high-affinity binding of pabinafusp alfa to transferrin receptors and passage across the BBB into neuronal cells. In addition, JCR has confirmed enzyme uptake in various brain tissues. The company has also confirmed a reduction of substrate accumulation in the CNS and peripheral organs in an animal model of Hunter syndrome. 1,2 In several clinical trials of pabinafusp alfa, JCR obtained evidence of reducing heparan sulfate concentrations in the cerebrospinal fluid, a biomarker for assessing effectiveness against CNS symptoms; these results were consistent with those obtained in pre-clinical studies. 3 Clinical studies have also demonstrated the positive effects of pabinafusp alfa on CNS symptoms. 4,5,6 About Mucopolysaccharidosis Type II (Hunter Syndrome) Mucopolysaccharidosis type II (MPS II, or Hunter syndrome) is an X-linked recessive lysosomal storage disorder caused by a deficiency of iduronate-2-sulfatase, an enzyme that breaks down complex carbohydrates called glycosaminoglycans (GAGs, also known as mucopolysaccharides) in the body. Hunter syndrome, which affects an estimated 2,000-3,000 individuals worldwide (according to JCR research), gives rise to a wide range of somatic and neurological symptoms. The current standard of care for Hunter syndrome is enzyme replacement therapy. Central nervous system symptoms related to MPS II have been unmet medical needs so far. About JCR Pharmaceuticals Co., Ltd. JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceutical company that develops treatments that go beyond rare diseases to solve the world's most complex healthcare challenges. We continue to build upon our 50-year legacy in Japan while expanding our global footprint into the U.S., Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, MPS II (Hunter syndrome), Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II, MPS IIIA and B (Sanfilippo syndrome type A and B), and more. Our core values – Putting people first, Forging our own path, Always advancing, and Committed to excellence – mean that the work we do benefits all our stakeholders, including employees, partners, and patients. We strive to expand the possibilities for patients while accelerating medical advancement at a global level. For more information, please visit JCR's global website: Cautionary Statement Regarding Forward-Looking Statements This document contains forward-looking statements that are subject to known and unknown risks and uncertainties, many of which are outside our control. Forward-looking statements often contain words such as 'believe,' 'estimate,' 'anticipate,' 'intend,' 'plan,' 'will,' 'would,' 'target' and similar references to future periods. All forward-looking statements regarding our plans, outlook, strategy and future business, financial performance and financial condition are based on judgments derived from the information available to us at this time. Factors or events that could cause our actual results to be materially different from those expressed in our forward-looking statements include, but are not limited to, a deterioration of economic conditions, a change in the legal or governmental system, a delay in launching a new product, impact on competitors' pricing and product strategies, a decline in marketing capabilities relating to our products, manufacturing difficulties or delays, an infringement of our intellectual property rights, an adverse court decision in a significant lawsuit and regulatory actions. This document involves information on pharmaceutical products (including those under development). However, it is not intended for advertising or providing medical advice. Furthermore, it is intended to provide information on our company and businesses and not to solicit investment in securities we issue. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the factors that could cause actual results to differ materially, even if new information becomes available in the future. 2: Morimoto, et al. Clearance of heparin sulfate in the brain prevents neurodegeneration and neurocognitive impairment in MPS II mice. Mol. Ther. 2021; 29(5): 1853-1861. 3: Okuyama, et al. Iduronate-2-sulfatase with Anti-human Transferrin Receptor Antibody for Neuropathic Mucopolysaccharidosis II: A Phase 1/2 Trial. Mol Ther. 2020; 27(2): 456-464. 4: Okuyama, et al. A Phase 2/3 Trial of Pabinafusp Alfa, IDS Fused with Anti-Human Transferrin Receptor Antibody, Targeting Neurodegeneration in MPS-II. Mol Ther. 2021; 29(2): 671-679. 5: Giugliani, et al. Iduronate-2-sulfatase fused with anti-human transferrin receptor antibody, pabinafusp alfa, for treatment of neuronopathic and non-neuronopathic mucopolysaccharidosis II: Report of a phase 2 trial in Brazil. Mol Ther. 2021; 29(7): 2378-2386. 6: Giugliani, et al. Enzyme Replacement Therapy with Pabinafusp Alfa for Neuronopathic Mucopolysaccharidosis II; an Integrated Analysis of Preclinical and Clinical Data. Int. J. Mol. Sci. 2021, Volume 22, Issue 20, 10938. View source version on CONTACT: Investors & Media: JCR Pharmaceuticals Co., Ltd. Corporate Communications [email protected] KEYWORD: UNITED STATES JAPAN NORTH AMERICA ASIA PACIFIC INDUSTRY KEYWORD: RESEARCH NEUROLOGY CLINICAL TRIALS BIOTECHNOLOGY HEALTH PHARMACEUTICAL GENERAL HEALTH OTHER SCIENCE SCIENCE SOURCE: JCR Pharmaceuticals Co., Ltd. Copyright Business Wire 2025. PUB: 07/02/2025 11:12 AM/DISC: 07/02/2025 11:12 AM


Business Wire
a day ago
- Business Wire
JCR Pharmaceuticals Announces the Achievement of Enrollment in the JR-141 Global Phase III Clinical Trial
HYOGO, Japan--(BUSINESS WIRE)--JCR Pharmaceuticals Co., Ltd. (TSE 4552; JCR) announced that it achieved the enrollment of the target number of participants in the global Phase III clinical trial of JR-141 (INN: pabinafusp alfa), which is in development for the treatment of mucopolysaccharidosis type II (MPS II, also known as Hunter syndrome). The Phase III clinical trial is ongoing in the United States, Latin America, and Europe. (JR-141-GS31) JR-141 is a recombinant fusion protein of an antibody against the human transferrin receptor and iduronate-2-sulfatase, the enzyme that is missing or malfunctioning in people with Hunter syndrome. JR-141 was developed using J-Brain Cargo®, JCR's proprietary blood-brain barrier (BBB)-penetrating technology, which is designed to deliver biotherapeutics across the BBB into the central nervous system (CNS) to address the neurological symptoms of Hunter syndrome. 'This achievement is a milestone in the JR-141 clinical development program, as the Hunter syndrome community needs a therapy that treats the cognitive symptoms of this devastating and life-threatening disease for which there are inadequate treatment options available,' said Shin Ashida, Chairman, President and CEO of JCR Pharmaceuticals. 'We are making good progress in this global Phase III clinical trial, and we look forward to sharing the clinical data as they are available. Thank you to all the participants who are part of this clinical trial.' In March 2021, the Ministry of Health, Labour and Welfare (MHLW) in Japan approved JR-141 (also known by the brand name IZCARGO®) for a lysosomal storage disorder. JR-141 is the first-ever approved ERT in the world that penetrates the BBB. About JR-141 JR-141 (INN: pabinafusp alfa) is a recombinant fusion protein of an antibody against the human transferrin receptor and iduronate-2-sulfatase, the enzyme that is missing or malfunctioning in subjects with Hunter syndrome. It incorporates J-Brain Cargo®, JCR's proprietary blood-brain barrier (BBB)-penetrating technology, to cross the BBB through transferrin receptor-mediated transcytosis, and its uptake into cells is mediated through the mannose-6-phosphate receptor. This novel mechanism of action is expected to make JR-141 effective against the central nervous system (CNS) symptoms of Hunter syndrome. In non-clinical trials, JCR has confirmed both high-affinity binding of pabinafusp alfa to transferrin receptors and passage across the BBB into neuronal cells. In addition, JCR has confirmed enzyme uptake in various brain tissues. The company has also confirmed a reduction of substrate accumulation in the CNS and peripheral organs in an animal model of Hunter syndrome.1,2 In several clinical trials of pabinafusp alfa, JCR obtained evidence of reducing heparan sulfate concentrations in the cerebrospinal fluid, a biomarker for assessing effectiveness against CNS symptoms; these results were consistent with those obtained in pre-clinical studies.3 Clinical studies have also demonstrated the positive effects of pabinafusp alfa on CNS symptoms.4,5,6 About Mucopolysaccharidosis Type II (Hunter Syndrome) Mucopolysaccharidosis type II (MPS II, or Hunter syndrome) is an X-linked recessive lysosomal storage disorder caused by a deficiency of iduronate-2-sulfatase, an enzyme that breaks down complex carbohydrates called glycosaminoglycans (GAGs, also known as mucopolysaccharides) in the body. Hunter syndrome, which affects an estimated 2,000-3,000 individuals worldwide (according to JCR research), gives rise to a wide range of somatic and neurological symptoms. The current standard of care for Hunter syndrome is enzyme replacement therapy. Central nervous system symptoms related to MPS II have been unmet medical needs so far. About JCR Pharmaceuticals Co., Ltd. JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceutical company that develops treatments that go beyond rare diseases to solve the world's most complex healthcare challenges. We continue to build upon our 50-year legacy in Japan while expanding our global footprint into the U.S., Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, MPS II (Hunter syndrome), Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II, MPS IIIA and B (Sanfilippo syndrome type A and B), and more. Our core values – Putting people first, Forging our own path, Always advancing, and Committed to excellence – mean that the work we do benefits all our stakeholders, including employees, partners, and patients. We strive to expand the possibilities for patients while accelerating medical advancement at a global level. For more information, please visit JCR's global website: Cautionary Statement Regarding Forward-Looking Statements This document contains forward-looking statements that are subject to known and unknown risks and uncertainties, many of which are outside our control. Forward-looking statements often contain words such as 'believe,' 'estimate,' 'anticipate,' 'intend,' 'plan,' 'will,' 'would,' 'target' and similar references to future periods. All forward-looking statements regarding our plans, outlook, strategy and future business, financial performance and financial condition are based on judgments derived from the information available to us at this time. Factors or events that could cause our actual results to be materially different from those expressed in our forward-looking statements include, but are not limited to, a deterioration of economic conditions, a change in the legal or governmental system, a delay in launching a new product, impact on competitors' pricing and product strategies, a decline in marketing capabilities relating to our products, manufacturing difficulties or delays, an infringement of our intellectual property rights, an adverse court decision in a significant lawsuit and regulatory actions. This document involves information on pharmaceutical products (including those under development). However, it is not intended for advertising or providing medical advice. Furthermore, it is intended to provide information on our company and businesses and not to solicit investment in securities we issue. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the factors that could cause actual results to differ materially, even if new information becomes available in the future. References 1: Sonoda, et al. A blood-brain-barrier-penetrating anti-human transferrin receptor antibody fusion protein for neuronopathic mucopolysaccharidosis II. Mol. Ther. 2018; 26(5):1366-1374. 2: Morimoto, et al. Clearance of heparin sulfate in the brain prevents neurodegeneration and neurocognitive impairment in MPS II mice. Mol. Ther. 2021; 29(5): 1853-1861. 3: Okuyama, et al. Iduronate-2-sulfatase with Anti-human Transferrin Receptor Antibody for Neuropathic Mucopolysaccharidosis II: A Phase 1/2 Trial. Mol Ther. 2020; 27(2): 456-464. 4: Okuyama, et al. A Phase 2/3 Trial of Pabinafusp Alfa, IDS Fused with Anti-Human Transferrin Receptor Antibody, Targeting Neurodegeneration in MPS-II. Mol Ther. 2021; 29(2): 671-679. 5: Giugliani, et al. Iduronate-2-sulfatase fused with anti-human transferrin receptor antibody, pabinafusp alfa, for treatment of neuronopathic and non-neuronopathic mucopolysaccharidosis II: Report of a phase 2 trial in Brazil. Mol Ther. 2021; 29(7): 2378-2386. 6: Giugliani, et al. Enzyme Replacement Therapy with Pabinafusp Alfa for Neuronopathic Mucopolysaccharidosis II; an Integrated Analysis of Preclinical and Clinical Data. Int. J. Mol. Sci. 2021, Volume 22, Issue 20, 10938.


Miami Herald
25-06-2025
- Miami Herald
Parasitic creatures — living in spider egg sacs — found as new species in India
Across the regions of West Bengal, India, a group of researchers were on the hunt for the egg sacs of spiders. Between 2021 and 2023, they searched near farmland and natural environments alike until they found the groups of eggs. 'Spider egg sacs, along with guarding mother spiders, whenever encountered were collected from different localities in West Bengal,' researchers said in a study published June 23 in the peer-reviewed European Journal of Taxonomy. The researchers weren't after the spiders — they wanted the parasites hidden within. 'Each spider egg sac was carefully placed in a labelled vial and covered by muslin cloth,' researchers said. 'These vials were kept at room temperature (75 to 77 degrees Fahrenheit) in the lab for one month to monitor the emergence of spiderlings and parasitoids.' What emerged from the egg sacs were members of the Idris genus of parasitic wasps, according to the study. The group is known as 'gregarious' parasites, meaning more than one parasite is depositing in each host, in this case the egg sacs. When the wasps were reared from the eggs, they were revealed to belong to four new species, according to the study. The first new species is Idris bianor, named after the spider genus it parasitizes, according to the study. Its body length is just 0.02 to 0.03 inches long, researchers said, and its body is light brown, reddish brown and pale yellow with brownish black patches. The species is found in West Bengal, India, as well as in Pakistan, according to the study. Idris furvus, the second new species, was named after the Latin word for 'black,' and references its body color, according to the study. The wasp is predominantly black, with 'honey brown' legs and antennae, researchers said. The black Idris wasp is a bit larger than the bianor wasp, measuring 0.05 inches long, according to the study. The species has only been found in West Bengal, researchers said. The third new species is named Idris hyllus, again named after the host spider it parasitizes. The head and body are 'honey brown to yellow,' with 'pale yellow' mandibles that are 'reddish-brown' on the tip, according to the study. Only females of the species were discovered, researchers said. The last species, Idris longiscapus, was named after the 'elongated scape characteristic of this species,' or the section of antennae closest to the wasp's head, according to the study. Similar in size to the other species, the wasp is 'brownish black' with 'yellow' legs and antennae and white hairs on the body, researchers said. The species is found in West Bengal and Pakistan, researchers said. Parasitic wasps are a group of wasps that rely on other species to complete their life cycles, according to the University of Minnesota. They are all generally very small and lay eggs either in the eggs of another species or in another species itself the university said. Parasitic wasps don't build a hive or have a queen, and instead lead solitary lives that begin hidden. When the wasps emerge from a parasitized insect, the insect dies, according to the university. All four species were found in West Bengal, a state on the far eastern border of India, just west of Bangladesh. The research team includes V. Sushama, Rupam Debnath, K. Rajmohana and K.P. Dinesh.